Downloading...
Download

Crispr

100% Buy Signal on CRSPThe Megalodon indicators are giving us a buy signal on CRSP Therapeutics! The backtesting results are 100% on this stock so don't miss out on these profits! The Megalodon indicator uses a machine learning algorithm, combined with data from over 500 buy setups, and over 2000 indicators to produce extremely accurate buy signals on any and all asset classes! You will also receive real time buy and sell signals for the stock market, cryptocurrency, as well as forex markets! We also busy completed our cryptocurrency automated trade bot. It trades for you, using our backtested indicator with phenomenal results! So try it today!!!
NASDAQ:CRSPLong
by RandallGurule
1
Investing In Genomics Anyone who knows me personally is cognisant of the fact that I hail from a pharmacy background that involves managing a community pharmacy in my day-to-day life. While this blog is focused on investing in macroeconomics and having a fundamental macroeconomic outlook, today I am heeding the advice of Peter Lynch; ‘‘you don’t have to go looking for investment opportunities and ideas all over the world. Start with what you know and what you are involved in, in your day to day life’’. Following this advice, I will share what I think is a potentially fantastic opportunity for readers interested in investing in healthcare. This opportunity lies in CRISPR. Looking back in recent history, it took over 13 years and an immense amount of computing power to map out the human genome. The process started in 2001 and cost 2.7 billion USD, 12 years later in 2012 CRISPR based genome-editing was birthed. In 2013 the cost to sequence a human genome has dropped from 2.7billion USD to 1000 USD. This deflationary trend is projected to continue into the 2020s and 2030s thus implying human gene sequencing will get cheaper and more affordable over time. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genome-editing platform that dares to address the most salient health issues. read more at www.patreon.com NASDAQ:CRSP Many Thanks. R.M.D
NASDAQ:CRSP
by couragepharm
EDIT off the bounce on low volume.Nice support level at $20 Filled Gap up and Gap down. If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels. CRISPR got upgraded. EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally. Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.
NASDAQ:EDITLong
by tonyyubc